Neurocrine Biosciences, Inc.

As of June 30, 2026, Neurocrine Biosciences, Inc. carries a market capitalization of 17.25B, placing it among publicly traded companies globally. Its enterprise value stands at 17.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neurocrine Biosciences, Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Neurocrine Biosciences, Inc. has 101.60M shares outstanding.

As of June 30, 2026, Neurocrine Biosciences, Inc. trades at a trailing price-to-earnings ratio of 24.12. The price-to-sales ratio is 5.04, and the price-to-book ratio stands at 4.67.

As of June 30, 2026, Neurocrine Biosciences, Inc. trades at an EV/EBITDA multiple of 20.50 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Neurocrine Biosciences, Inc. trades at an EV/FCF ratio of 19.18, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 17.27B versus a market cap of 17.25B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Neurocrine Biosciences, Inc. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.88, indicating elevated leverage, while an interest coverage ratio of 290.38 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. posted a return on equity (ROE) of 22.09, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 19.58, useful for judging operating efficiency across full business cycles. The company generates approximately 1.73M in revenue per employee across its workforce of 1,950.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.85 indicates how many times Neurocrine Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. recorded 234.70M in income tax expense. That works out to an effective tax rate of 24.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 940.20M, leaving 705.50M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Neurocrine Biosciences, Inc.'s stock has declined approximately 1.22% over the past 52 weeks. The 50-day moving average sits at 147.47, while the 200-day moving average is 147.21.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. generated 3.37B in revenue and converted that into 705.50M in net income, yielding earnings per share of 6.82. EBITDA reached 842.10M, while operating income came in at 806.20M.

As of June 30, 2026, Neurocrine Biosciences, Inc. holds 389.80M in cash and equivalents against 401.80M in total debt, resulting in a net debt position of -332.40M. Total book value stands at 3.69B, with working capital of 763.00M providing operational flexibility.

Neurocrine Biosciences, Inc. produced 898.10M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Neurocrine Biosciences, Inc. posted a gross margin of 97.97, reflecting its pricing power and cost economics. The operating margin of 23.90 and net profit margin of 20.91 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 5.11, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.35, meaning Neurocrine Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Neurocrine Biosciences, Inc. has an Altman Z-Score of 9.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.